United States Department of Defense

Dr. Huang's lab studies prostate cancer genetics, focusing on African Americans. The Hollander Foundation awarded him $25,000 for research. Dr. Robert Hollander, a prostate cancer survivor and winemaker, funds the foundation to support prostate cancer research.

A study by Weill Cornell Medicine and New York Genome Center identifies antiviral enzymes and standard chemotherapy as key mutagens in bladder cancer development, with overactive genes in circular DNA structures driving therapy resistance, offering new therapeutic strategies.

A study by Weill Cornell Medicine and New York Genome Center identifies antiviral enzymes and chemotherapy as key mutagens in bladder cancer, with overactive genes in circular DNA structures driving therapy resistance, offering new therapeutic targets.

New human H5 influenza cases in California, Marburg vaccine trial in Rwanda, and chem-bio AI model safety considerations.

The European Commission granted NLX-112 (Neurolixis) orphan medicinal product designation for treating spinocerebellar ataxia (SCA), based on successful preclinical trials showing significant motor dysfunction reduction in SCA3 models. This designation offers 10 years of market exclusivity, with potential for an additional 2 years if a pediatric assessment plan is met. NLX-112, an oral serotonin 5-HT1A receptor agonist, has also shown efficacy in Parkinson's disease trials, reducing levodopa-induced dyskinesia and motor impairment.